Insulin-like Growth Factors in a clinical setting: Review of IGF-I

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33154838" target="_blank" >RIV/61989592:15110/15:33154838 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/15:#0000891

Výsledek na webu

<a href="http://dx.doi.org/10.5507/bp.2015.041" target="_blank" >http://dx.doi.org/10.5507/bp.2015.041</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2015.041" target="_blank" >10.5507/bp.2015.041</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Insulin-like Growth Factors in a clinical setting: Review of IGF-I

Popis výsledku v původním jazyce

Interest in growth hormone (GH) is inextricably linked to the need for in depth understanding of the somatomedins (insulin-like growth factors) which are polypeptides structurally similar to insulin and with broad physiological aktivity. To date, the most commonly konwn is Insulin-Like Growth Factor I (IGF-I). Despite considerable current knowledge of IGF-I, however, its bioaktivity is incompletely understood. Measurement of IGF-I is of the utmost importance in the diagnosis and treatment of, for example acromegaly and growth hormone deficiency. The development of recombinant IGF-I, has allowed its use in such cases. Clinical practice, however, shows that few young/adult patients will benefit from treatment with the rIGF-I, mecasermin, given the numberof adverse effects found. This review focuses on current knowledge mainly related to IGF-I and the use of its recombinant form (fIGF-I) in clinical practice. Several functions of IGI-II have been elucidated but their clinical signifikanc

Název v anglickém jazyce

Insulin-like Growth Factors in a clinical setting: Review of IGF-I

Popis výsledku anglicky

Interest in growth hormone (GH) is inextricably linked to the need for in depth understanding of the somatomedins (insulin-like growth factors) which are polypeptides structurally similar to insulin and with broad physiological aktivity. To date, the most commonly konwn is Insulin-Like Growth Factor I (IGF-I). Despite considerable current knowledge of IGF-I, however, its bioaktivity is incompletely understood. Measurement of IGF-I is of the utmost importance in the diagnosis and treatment of, for example acromegaly and growth hormone deficiency. The development of recombinant IGF-I, has allowed its use in such cases. Clinical practice, however, shows that few young/adult patients will benefit from treatment with the rIGF-I, mecasermin, given the numberof adverse effects found. This review focuses on current knowledge mainly related to IGF-I and the use of its recombinant form (fIGF-I) in clinical practice. Several functions of IGI-II have been elucidated but their clinical signifikanc

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers-Olomouc

ISSN

1213-8118

e-ISSN

—

Svazek periodika

159

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

347-351

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—